Literature DB >> 24628096

Guttate psoriasis is associated with an intermediate phenotype of impaired Langerhans cell migration.

L H Eaton1, L Chularojanamontri, F R Ali, E Theodorakopoulou, R J Dearman, I Kimber, C E M Griffiths.   

Abstract

BACKGROUND: An episode of guttate psoriasis can be an isolated event, can recur as guttate episodes, or develop into chronic plaque psoriasis (CPP). A previous study revealed that early-onset (before age 40 years) CPP is associated with inhibition of epidermal Langerhans cell (LC) migration.
OBJECTIVES: To determine whether guttate psoriasis is also associated with abnormal LC mobilization.
METHODS: Three groups of patients were recruited: current guttate episode (n = 5); guttate psoriasis progressed to CPP (n = 6); and resolved guttate psoriasis (n = 2). Biopsies were taken from uninvolved skin and LC migration was measured ex vivo using an epidermal explant model.
RESULTS: Patients with a current episode of guttate psoriasis displayed epidermal LC migration, although the extent was significantly lower than in skin from healthy controls (P < 0·05). In contrast, in those patients in whom guttate psoriasis developed into CPP there was no mobilization of LC. Finally, in patients in whom guttate psoriasis had resolved, LC migration was normal.
CONCLUSIONS: We have shown that guttate psoriasis is associated with an abnormality of LC mobilization, but a less marked inhibition compared with that seen in CPP. In resolved guttate psoriasis LC function returns to normal. These data provide further evidence that the pathogenesis of psoriasis is characterized by significant changes in epidermal LC function.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2014        PMID: 24628096     DOI: 10.1111/bjd.12960

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

1.  A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality.

Authors:  Akshay Flora; John W Frew
Journal:  JAAD Case Rep       Date:  2022-05-05

2.  Usefulness of Skin Explants for Histologic Analysis after Fractional Photothermolysis.

Authors:  Gyeong-Hun Park; Sung Eun Chang; Seunghyun Bang; Kwang Hee Won; Chong Hyun Won; Mi Woo Lee; Jee Ho Choi; Kee Chan Moon
Journal:  Ann Dermatol       Date:  2015-05-29       Impact factor: 1.444

Review 3.  Human Langerhans Cells with Pro-inflammatory Features Relocate within Psoriasis Lesions.

Authors:  Liv Eidsmo; Elisa Martini
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561

4.  Genome-wide transcriptome analysis identifies alternative splicing regulatory network and key splicing factors in mouse and human psoriasis.

Authors:  Jin Li; Peng Yu
Journal:  Sci Rep       Date:  2018-03-07       Impact factor: 4.379

5.  Antigen-Presenting Cells in Psoriasis.

Authors:  Dóra Antal; Shahrzad Alimohammadi; Péter Bai; Attila Gábor Szöllősi; Magdolna Szántó
Journal:  Life (Basel)       Date:  2022-02-03

6.  Abnormal lipid metabolism in epidermal Langerhans cells mediates psoriasis-like dermatitis.

Authors:  Xilin Zhang; Xiaorui Li; Yuanyuan Wang; Youdong Chen; Yijun Hu; Chunyuan Guo; Zengyang Yu; Peng Xu; Yangfeng Ding; Qing-Sheng Mi; Jianhua Wu; Jun Gu; Yuling Shi
Journal:  JCI Insight       Date:  2022-07-08

Review 7.  Treating pediatric plaque psoriasis: challenges and solutions.

Authors:  Jayakar Thomas; Kumar Parimalam
Journal:  Pediatric Health Med Ther       Date:  2016-04-21

Review 8.  The role of Langerhans cells in epidermal homeostasis and pathogenesis of psoriasis.

Authors:  Bei Yan; Nian Liu; Jie Li; Jiaoduan Li; Wu Zhu; Yehong Kuang; Xiang Chen; Cong Peng
Journal:  J Cell Mol Med       Date:  2020-09-11       Impact factor: 5.310

9.  Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a.

Authors:  Ka Lun Cheung; Rachael Jarrett; Sumithra Subramaniam; Maryam Salimi; Danuta Gutowska-Owsiak; Yi-Ling Chen; Clare Hardman; Luzheng Xue; Vincenzo Cerundolo; Graham Ogg
Journal:  J Exp Med       Date:  2016-09-26       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.